查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1522123

精神科數位生物標記市場 - 按類型、臨床實踐、最終用戶、地區和競爭細分的全球行業規模、佔有率、趨勢、機會和預測，2019-2029F

Psychiatric Digital Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type, By Clinical Practice, By End User, By Region & Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球精神科數位生物標記市場估值為5.2005 億美元，預計在預測期內將強勁成長，到2029 年複合年成長率為18.25%。物的開發、資料和使用。該市場涵蓋一系列工具，包括穿戴式裝置、行動應用程式以及追蹤情緒、認知功能和其他心理健康指標的軟體。

市場概況
預測期 2025-2029
2023 年市場規模 52005萬美元
2029 年市場規模 14.2480億美元
2024-2029 年複合年成長率 18.25%
成長最快的細分市場 穿戴式
最大的市場 北美洲

該市場的成長主要是由憂鬱症、焦慮症、躁鬱症和精神分裂症等心理健康疾病發病率上升所推動的，這增加了對先進監測和診斷工具的需求。在技​​術進步、個人化醫療轉變和投資增加的支持下，市場正在強勁擴張。

市場多元化，產品類型多樣，區域差異顯著，競爭格局既有成熟企業，也有創新新創企業。儘管面臨資料隱私問題和監管複雜性等挑戰，但在持續的技術創新和更廣泛的市場採用的推動下，仍存在巨大的成長機會。

主要市場促進因素

精神疾病的盛行率不斷增加

日益關注個人化醫療

技術進步

主要市場挑戰

資料隱私和安全問題

監管和報銷挑戰

臨床驗證和功效證據

主要市場趨勢

人工智慧 (AI) 和機器學習 (ML) 的進步

數位生物標記與遠距醫療和遠端監控的整合

日益關注個人化和精準醫療

細分市場洞察

類型洞察

臨床實務見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球精神科數位生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（穿戴式、基於行動的應用程式、感測器、其他）
    • 按臨床實踐（診斷精神病數位生物標記、監測精神病數位生物標記、預測和預後精神病數位生物標記、其他）
    • 按最終用戶（醫療保健公司、醫療保健提供者、付款人、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美精神科數位生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 透過臨床實踐
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲精神科數位生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 透過臨床實踐
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區精神科數位生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 透過臨床實踐
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美精神科數位生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 透過臨床實踐
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲精神科數位生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 透過臨床實踐
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球精神科數位生物標記市場：SWOT 分析

第14章：競爭格局

  • Koneksa Health Inc
  • Biogen, Inc
  • Empatica Inc
  • VivoSense, Inc
  • IXICO plc
  • Huma Therapeutics Limited
  • Sonde Health, Inc
  • Clario

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 24382

Global Psychiatric Digital Biomarkers Market was valued at USD 520.05 million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 18.25% through 2029. The global psychiatric digital biomarkers market focuses on the development, implementation, and use of digital technologies designed to measure and analyze physiological and behavioral data for the diagnosis, monitoring, and treatment of psychiatric disorders. This market encompasses a range of tools including wearable devices, mobile applications, and software that track mood, cognitive functions, and other mental health metrics.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 520.05 Million
Market Size 2029USD 1424.80 Million
CAGR 2024-202918.25%
Fastest Growing SegmentWearable
Largest MarketNorth America

The growth of this market is primarily driven by the rising incidence of mental health conditions such as depression, anxiety, bipolar disorder, and schizophrenia, which heightens the need for advanced monitoring and diagnostic tools. The market is expanding robustly, supported by technological advancements, the shift towards personalized medicine, and increasing investments.

The market is diverse, with various product types, notable regional differences, and a competitive landscape that includes both established companies and innovative startups. Despite facing challenges such as data privacy concerns and regulatory complexities, significant growth opportunities exist, fueled by ongoing technological innovation and broader market adoption.

Key Market Drivers

Increasing Prevalence of Psychiatric Disorders

Healthcare providers require advanced diagnostic and monitoring tools to address the growing patient population with psychiatric conditions. Digital biomarkers offer innovative solutions for continuous monitoring and more precise assessments, addressing this increased demand. With a higher incidence of psychiatric disorders, early detection becomes crucial for effective intervention and treatment. Digital biomarkers enable real-time tracking of symptoms and behaviors, facilitating earlier identification and prompt action to manage psychiatric conditions. The rise in psychiatric disorders places additional strain on healthcare systems, which drives the adoption of digital biomarkers as a means to alleviate this burden. An increased patient load requires more efficient management of healthcare resources. Digital biomarkers provide continuous monitoring and data collection, reducing the need for frequent in-person visits and enabling more efficient use of healthcare resources. Managing chronic psychiatric conditions can be costly. Digital biomarkers offer a way to monitor patients remotely, potentially reducing hospitalizations and emergency visits, which helps in controlling overall healthcare costs.

The growing number of patients with psychiatric conditions drives the need for improved care and better patient outcomes, which digital biomarkers can support. With a larger patient population, there is a greater need for personalized treatment approaches. Digital biomarkers provide detailed, individualized data that supports tailored treatment plans, enhancing the effectiveness of interventions and improving patient outcomes. For chronic psychiatric conditions, ongoing management is crucial. Digital biomarkers enable continuous monitoring of patient progress, allowing for timely adjustments to treatment plans and improving long-term care. The rising prevalence of psychiatric disorders stimulates research and development efforts to create new solutions and improve existing ones, driving innovation in the digital biomarkers market. Increased prevalence leads to greater investment in R&D to develop new digital biomarkers and enhance existing technologies. This investment fosters innovation and accelerates the introduction of advanced digital solutions to the market. The need for new and effective diagnostic tools drives clinical trials and validation studies for digital biomarkers. This research not only supports market growth but also ensures that new technologies meet clinical and regulatory standards.

The increasing awareness of psychiatric disorders among the public and institutions highlights the need for effective management tools, such as digital biomarkers. Greater public awareness of mental health issues drives demand for innovative solutions that can improve mental health management. Digital biomarkers address this need by providing cutting-edge tools for monitoring and assessment. Institutions, including healthcare organizations and governmental bodies, are more likely to support and fund initiatives that address the high prevalence of psychiatric disorders. This support includes backing for digital biomarkers as part of broader mental health strategies.

Increasing Growing Focus on Personalized Medicine

Personalized medicine emphasizes the development of individualized treatment plans based on unique patient characteristics. Digital biomarkers play a crucial role in this process by providing specific data on each patient's condition. Digital biomarkers provide detailed insights into a patient's physiological and behavioral data, allowing for a more precise understanding of their mental health condition. This data enables clinicians to tailor treatment plans to the individual's specific needs, enhancing the effectiveness of interventions. With the information from digital biomarkers, healthcare providers can customize therapies, including medication types and dosages, psychotherapy approaches, and lifestyle recommendations. This customization improves treatment outcomes and patient satisfaction.

Personalized medicine relies on accurate and detailed diagnostics to guide treatment decisions. Digital biomarkers enhance diagnostic accuracy by offering real-time and objective data. Digital biomarkers provide objective measurements of symptoms and behavioral patterns, reducing reliance on subjective assessments and improving diagnostic accuracy. This precision helps in distinguishing between different psychiatric disorders and tailoring appropriate treatments. By analyzing continuous data from digital biomarkers, clinicians can identify early signs of psychiatric conditions that may not be evident through traditional diagnostic methods. Early identification allows for timely and personalized interventions. The focus on personalized medicine is driven by the need for data-driven insights into individual health. Digital biomarkers offer valuable data that supports this approach. Digital biomarkers contribute to creating comprehensive patient profiles by tracking various aspects of mental health, including mood fluctuations, cognitive function, and physiological responses. These profiles support more informed and personalized treatment decisions. Advanced analytics of data from digital biomarkers can predict how patients will respond to specific treatments. This predictive capability allows for proactive adjustments to treatment plans, optimizing outcomes based on individual responses.

Personalized medicine often leads to higher patient engagement and adherence to treatment plans. Digital biomarkers contribute to this by offering interactive and user-friendly tools. Digital biomarkers provide patients with real-time feedback on their health status and treatment progress. This feedback enhances patient engagement by keeping individuals informed and involved in their own care. Access to personal health data empowers patients to make informed decisions about their treatment and lifestyle. Digital biomarkers facilitate this empowerment by delivering actionable insights that patients can use to actively manage their mental health. Personalized medicine often involves the integration of various technologies to create a cohesive treatment strategy. Digital biomarkers are increasingly integrated with other emerging technologies to support personalized care. The integration of digital biomarkers with Artificial Intelligence (AI) and Machine Learning (ML) enhances the ability to analyze complex data and develop personalized treatment plans. AI-driven insights from digital biomarkers improve decision-making and optimize therapeutic approaches. Digital biomarkers are frequently used in conjunction with telehealth platforms, enabling remote monitoring and virtual consultations. This integration supports personalized care by allowing continuous data collection and real-time adjustments to treatment plans.

Advancements in Technology

Technological advancements have greatly improved the ability to collect and process data relevant to psychiatric conditions. Modern sensors and wearable devices can track a wide range of physiological and behavioral metrics, such as heart rate variability, sleep patterns, and physical activity. These devices provide continuous, high-resolution data that is crucial for monitoring mental health conditions. Mobile applications have become sophisticated tools for tracking mood, cognitive function, and daily activities. Integration with wearable devices allows for seamless data collection and provides a comprehensive view of the patient's mental health.

Advances in data analytics, including artificial intelligence (AI) and machine learning (ML), enhance the ability to analyze and interpret complex data from digital biomarkers. AI and ML technologies can process and analyze large datasets to identify patterns and correlations that may not be apparent through traditional analysis. These algorithms improve the accuracy of diagnoses and the efficacy of personalized treatment plans. Advanced analytics enable predictive modeling, which can forecast the progression of psychiatric conditions and responses to treatments. This predictive capability supports early intervention and tailored therapeutic strategies. Technological advancements facilitate the integration of digital biomarkers with broader digital health ecosystems, enhancing their functionality and impact. Improved interoperability between digital biomarkers and electronic health records (EHRs) allows for seamless data exchange and integration into clinical workflows. This integration supports more coordinated and informed patient care. Technological advancements in telehealth platforms enable digital biomarkers to be used in remote monitoring and virtual consultations. This integration expands the reach of psychiatric care and provides continuous support to patients.

Technology has improved the user experience and accessibility of digital biomarkers, making them more appealing to both clinicians and patients. Advances in user interface design ensure that digital biomarkers are easy to use and navigate. Intuitive interfaces improve patient adherence and engagement by making data collection and management straightforward. Technological improvements have made digital biomarkers more accessible to diverse populations, including those with disabilities. Features such as voice commands, customizable displays, and compatibility with assistive technologies enhance usability. Technology enables the scalability and cost efficiency of digital biomarkers, making them more feasible for widespread adoption. Cloud-based platforms facilitate the storage, processing, and analysis of large volumes of data from digital biomarkers. This scalability supports the deployment of digital biomarkers across various healthcare settings and patient populations. Technological advancements have reduced the cost of developing and manufacturing digital biomarkers. Lower costs make these technologies more affordable for healthcare providers and patients, driving broader adoption.

Key Market Challenges

Data Privacy and Security Concerns

The collection and management of sensitive mental health data pose significant privacy and security challenges. As digital biomarkers often involve tracking personal health information, including behavioral and physiological data, ensuring its protection is crucial.

Stringent data protection regulations, such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA), impose strict requirements on how patient data is collected, stored, and shared. Compliance with these regulations can be complex and costly for companies in the digital biomarkers space. The increasing incidence of cyberattacks and data breaches raises concerns about the security of digital health data. A breach could lead to unauthorized access to sensitive patient information, undermining trust in digital biomarkers and potentially resulting in legal and financial repercussions.

Ensuring robust data privacy measures is essential for maintaining consumer trust. If patients perceive digital biomarkers as insecure or if their data is compromised, it could lead to reluctance in adopting these technologies, limiting market growth.

Regulatory and Reimbursement Challenges

Navigating the regulatory landscape and securing reimbursement for digital biomarkers can be challenging. The lack of standardized guidelines and reimbursement pathways creates barriers to market entry and adoption.

The regulatory environment for digital biomarkers is still evolving. Inconsistent guidelines and varying requirements across different regions can complicate the approval process for new digital biomarkers. This uncertainty can delay product development and market entry. Gaining reimbursement for digital biomarkers can be difficult due to the need to demonstrate clinical efficacy and cost-effectiveness. Payers may require extensive evidence of the clinical benefits and economic value of digital biomarkers before providing coverage. Without clear reimbursement pathways, adoption may be limited.

The absence of standardized protocols for the development and validation of digital biomarkers can hinder market growth. Standardization is crucial for ensuring consistency in data quality and comparability across different systems, which is essential for regulatory approval and market acceptance.

Clinical Validation and Evidence of Efficacy

Establishing the clinical validity and efficacy of digital biomarkers is essential for their widespread adoption. The need for rigorous validation and evidence of their effectiveness can be a significant challenge.

Conducting clinical trials and studies to validate digital biomarkers can be expensive and time-consuming. High costs associated with research and development may deter investment and slow the introduction of new biomarkers to the market. The long-term effectiveness and reliability of digital biomarkers often require extended periods of study. Limited long-term data can make it challenging to prove the sustained benefits and impact of these technologies, affecting their acceptance among clinicians and patients. Demonstrating that digital biomarkers can integrate seamlessly into existing clinical workflows and improve patient outcomes is crucial. If digital biomarkers do not align with established practices or show clear benefits over traditional methods, their adoption may be limited.

Key Market Trends

Advancements in Artificial Intelligence (AI) and Machine Learning (ML)

AI and ML technologies are revolutionizing the field of psychiatric digital biomarkers by enhancing the ability to analyze complex data sets and identify patterns that are not readily apparent to human clinicians. These advancements enable more precise and actionable insights into mental health conditions.

AI algorithms can process vast amounts of data from various sources, such as wearables, mobile apps, and electronic health records. They can identify subtle patterns and correlations in behavior, mood, and physiological metrics that aid in the accurate diagnosis and monitoring of psychiatric disorders.

Machine learning models can predict the onset of psychiatric conditions based on historical data and real-time inputs. This predictive capability allows for proactive intervention and personalized treatment strategies, potentially preventing the escalation of symptoms. AI-driven insights enable the development of highly personalized treatment plans. By analyzing individual patient data, AI can tailor interventions to specific needs, leading to more effective management of psychiatric conditions.

Integration of Digital Biomarkers with Telehealth and Remote Monitoring

The integration of digital biomarkers with telehealth platforms and remote monitoring solutions is transforming psychiatric care by enabling continuous, real-time patient monitoring and virtual consultations.

Telehealth and remote monitoring make psychiatric care more accessible to patients, particularly those in remote or underserved areas. Patients can receive ongoing care and support without the need for frequent in-person visits, which is crucial for managing chronic psychiatric conditions. Digital biomarkers integrated with telehealth platforms facilitate continuous monitoring of patients' mental health status. This ongoing data collection provides a more comprehensive view of patient progress and allows for timely adjustments to treatment plans.

The convenience of remote care often leads to increased patient engagement and adherence to treatment protocols. Digital tools integrated with telehealth platforms can also offer real-time feedback and support, enhancing overall patient experience.

Growing Focus on Personalized and Precision Medicine

The shift towards personalized and precision medicine is a significant trend in the global psychiatric digital biomarkers market. This approach emphasizes tailoring medical treatment to the individual characteristics of each patient, rather than using a one-size-fits-all model.

Digital biomarkers contribute to precision medicine by providing detailed, patient-specific information that informs the development of targeted therapies. This approach increases the likelihood of successful outcomes by addressing the unique needs and conditions of each patient. The integration of genetic, biometric, and environmental data with digital biomarkers enhances the precision of psychiatric assessments. By understanding the genetic and environmental factors influencing mental health, clinicians can design more effective and personalized treatment plans. Personalized medicine aims to optimize treatment outcomes by focusing on the individual's specific health profile. Digital biomarkers play a crucial role in monitoring treatment effectiveness and making data-driven adjustments, leading to improved management of psychiatric disorders.

Segmental Insights

Type Insights

Based on the category of type, the wearable segment emerged as the dominant in the global market for psychiatric digital biomarkers in 2023. Wearable devices, such as smartwatches and fitness trackers, offer real-time monitoring of physiological and behavioral data. This continuous data collection provides valuable insights into a patient's mental health status, including mood fluctuations, sleep patterns, and physical activity levels. Such capabilities make wearables an attractive option for tracking and managing psychiatric conditions, leading to their dominance in the market. Significant technological advancements in sensors and data analytics have greatly enhanced the functionality of wearable devices. Modern wearables are equipped with advanced sensors that can measure heart rate variability, skin conductance, and other biomarkers relevant to psychiatric conditions. These improvements in sensor technology contribute to the accuracy and reliability of digital biomarkers, driving the growth of the wearable segment.

The wearable segment benefits from a strong consumer preference for devices that seamlessly integrate into daily life. Wearables are often seen as more user-friendly compared to other digital biomarker solutions, such as mobile apps or standalone devices. Their ease of use and continuous data collection align with the growing trend of consumer health monitoring, thus bolstering their market share. Wearable devices often integrate with broader digital health ecosystems, including mobile apps and online platforms. This integration facilitates the aggregation and analysis of data from multiple sources, providing a comprehensive view of a patient's mental health. The ability to seamlessly connect with other health management tools enhances the attractiveness and utility of wearables in psychiatric care. These factors are expected to drive the growth of this segment.

Clinical Practice Insights

The diagnostic psychiatric digital biomarkers segment is projected to experience rapid growth during the forecast period. Diagnostic psychiatric digital biomarkers offer the potential for more precise and objective assessment of psychiatric conditions. These biomarkers provide data that can improve the accuracy of diagnoses by offering quantifiable measurements of symptoms and their variations. Enhanced diagnostic accuracy supports better patient stratification and tailored treatment approaches, driving demand for these biomarkers. Diagnostic digital biomarkers are increasingly being integrated with traditional psychiatric assessment methods, such as clinical interviews and psychological tests. This integration enhances the comprehensiveness of the diagnostic process, allowing clinicians to combine subjective patient reports with objective digital data. This synergy improves diagnostic reliability and contributes to the segment's prominence.

One of the significant advantages of diagnostic digital biomarkers is their ability to facilitate early detection of psychiatric disorders. By identifying subtle changes in behavior, physiological metrics, or cognitive patterns, these biomarkers can help in the early identification of mental health issues. Early detection allows for prompt intervention, which can lead to better treatment outcomes and reduced severity of conditions. Traditional psychiatric diagnoses often rely on subjective assessments and patient self-reports, which can be influenced by various factors. Diagnostic digital biomarkers provide objective measurements of symptoms, such as changes in sleep patterns, activity levels, or cognitive function. This objectivity reduces variability and improves the consistency of diagnoses, making these biomarkers a valuable tool in clinical practice. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant in the global psychiatric digital biomarkers market in 2023, holding the largest market share in terms of value. North America, particularly the United States and Canada, boasts a highly developed healthcare infrastructure. This includes cutting-edge medical research facilities, extensive clinical networks, and advanced technological capabilities. Such infrastructure supports the integration and application of digital biomarkers in psychiatric care, driving market growth.

North American companies and institutions lead in R&D for digital health technologies. Significant investments in innovation by both private and public sectors have led to the development of advanced digital biomarkers that offer precise, real-time insights into psychiatric conditions. This competitive edge in R&D fosters a conducive environment for market expansion. The region faces a high prevalence of psychiatric conditions, such as depression, anxiety, and bipolar disorder. This elevated demand for effective and personalized mental health management solutions propels the adoption of digital biomarkers, which promise improved diagnostic accuracy and treatment efficacy. There is considerable support from both governmental and private sectors in North America for digital health innovations. Policies and funding initiatives aimed at advancing mental health technologies and digital health ecosystems further enhance market growth. Initiatives like the U.S. National Institutes of Health's (NIH) investment in digital mental health tools underscore this support.

North America exhibits a high adoption rate of digital health technologies. This is due to a technologically savvy population, widespread use of smartphones and wearable devices, and a strong culture of innovation. The integration of digital biomarkers into routine psychiatric practice aligns well with these trends, driving further market penetration. The region is home to several prominent market players and startups specializing in psychiatric digital biomarkers. These companies benefit from access to venture capital, partnerships with leading healthcare providers, and collaborations with academic institutions. Their presence and activity significantly contribute to North America's leadership in the global market.

Key Market Players

Koneksa Health Inc

Biogen, Inc

Empatica Inc

VivoSense, Inc

IXICO plc

Huma Therapeutics Limited

Sonde Health, Inc

Clario

Report Scope:

In this report, the Global Psychiatric Digital Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psychiatric Digital Biomarkers Market, By Type:

    Wearable Mobile based Applications Sensors Others

Psychiatric Digital Biomarkers Market, By Clinical Practice:

    Diagnostic Psychiatric Digital Biomarkers Monitoring Psychiatric Digital Biomarkers Predictive and Prognostic Psychiatric Digital Biomarkers Other

Psychiatric Digital Biomarkers Market, By End User:

    Healthcare companies Healthcare Providers Payers Others

Psychiatric Digital Biomarkers Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psychiatric Digital Biomarkers Market.

Available Customizations:

Global Psychiatric Digital Biomarkers market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Source
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psychiatric Digital Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Wearable, Mobile based Applications, Sensors, Others)
    • 5.2.2. By Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers, Other)
    • 5.2.3. By End User (Healthcare companies, Healthcare Providers, Payers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map

6. North America Psychiatric Digital Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Clinical Practice
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psychiatric Digital Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Clinical Practice
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Psychiatric Digital Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Clinical Practice
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Psychiatric Digital Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Clinical Practice
        • 6.3.3.2.3. By End User

7. Europe Psychiatric Digital Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Clinical Practice
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Psychiatric Digital Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Clinical Practice
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Psychiatric Digital Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Clinical Practice
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Psychiatric Digital Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Clinical Practice
        • 7.3.3.2.3. By End User
    • 7.3.4. France Psychiatric Digital Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Clinical Practice
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Psychiatric Digital Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Clinical Practice
        • 7.3.5.2.3. By End User

8. Asia-Pacific Psychiatric Digital Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Clinical Practice
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Psychiatric Digital Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Clinical Practice
        • 8.3.1.2.3. By End User
    • 8.3.2. India Psychiatric Digital Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Clinical Practice
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Psychiatric Digital Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Clinical Practice
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Psychiatric Digital Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Clinical Practice
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Psychiatric Digital Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Clinical Practice
        • 8.3.5.2.3. By End User

9. South America Psychiatric Digital Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Clinical Practice
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Psychiatric Digital Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Clinical Practice
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Psychiatric Digital Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Clinical Practice
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Psychiatric Digital Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Clinical Practice
        • 9.3.3.2.3. By End User

10. Middle East and Africa Psychiatric Digital Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Clinical Practice
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Psychiatric Digital Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Clinical Practice
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Psychiatric Digital Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Clinical Practice
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Psychiatric Digital Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Clinical Practice
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Psychiatric Digital Biomarkers Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Koneksa Health Inc
    • 14.1.1. Business Overview
    • 14.1.2. Financials (If Listed)
    • 14.1.3. Product & Service Offerings
    • 14.1.4. Recent Developments
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Biogen, Inc
  • 14.3. Empatica Inc
  • 14.4. VivoSense, Inc
  • 14.5. IXICO plc
  • 14.6. Huma Therapeutics Limited
  • 14.7. Sonde Health, Inc
  • 14.8. Clario

15. Strategic Recommendations

16. About Us & Disclaimer